Thank goodness for this question because without, it there would be massive unemployment among clinical research personnel, including trial coordinating centers, core labs, site investigators and coordinators, institutional review boards, registry personnel, and all the journal editors, reviewers and publishers. Oh, and I forgot, scientific program directors and countless more. It does seem that a huge industry has grown up around what to do to keep those bits of metal we put in coronary arteries from clotting. This effort has not been in vain, as stent thrombosis is now very unusual, and a lot of people have learned about trial design and statistical methods. Nonetheless, after hundreds of thousands (maybe a million) patients have been studied, shouldn’t we know exactly what to do?